Transitional cell carcinoma of the prostate: response to treatment with cisplatinum and cyclophosphamide.
We observed a remarkable clinical response to cisplatinum and cyclophosphamide in a patient with widespread metastatic transitional cell cancer of the prostate after hormonal therapy proved ineffective. Combination chemotherapy has the potential for an impressive response in these patients.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy* / Q000473:pathology; D002945:Cisplatin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D006801:Humans; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology
D003520:Cyclophosphamide; D002945:Cisplatin